Evidence map›Paper›PMID 31881875›Full record

Observational studyBMC urology2019

The resonance® metallic ureteral stent in the treatment of malignant ureteral obstruction: a prospective observational study.

Jun Miyazaki, Mizuki Onozawa, Satoshi Takahashi, Yuka Maekawa, Mitsuru Yasuda, Koichiro Wada, Yuji Maeda, Takuro Masaki, Akito Yamaguchi, Masahiko Suzuki and 6 more

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in BMC urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. A Qualitative Review of Clinical Decision-Making Using [Journal of medical radiation sciences · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 11 institutions in 1 country.

Jun MiyazakiDepartment of Urology, International University of Health and Welfare, 6-1-14 Kounodai, Ichikawa City, Chiba, 272-0827, Japan. jmiyazaki@iuhw.ac.jp.
Mizuki OnozawaDepartment of Urology, International University of Health and Welfare, 6-1-14 Kounodai, Ichikawa City, Chiba, 272-0827, Japan.
Satoshi TakahashiDepartment of Infection Control and Laboratory Medicine, Sapporo Medical University School of Medicine, S1 W16, Chuo-ku, Sapporo, 060-8543, Japan.
Yuka MaekawaDepartment of Urology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu City, 501-1194, Japan.
Mitsuru YasudaDepartment of Urology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu City, 501-1194, Japan.
Koichiro WadaDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Yuji MaedaDepartment of Urology, Public Central Hospital of Matto Ishikawa, 3-8 Kuramitsu, Hakusan-shi, Ishikawa, 924-0865, Japan.
Takuro MasakiDepartment of Urology, Harasanshin Hospital, 1-8 Taihaku-machi, Hakata-ku, Fukuoka City, Fukuoka, 812-0033, Japan.
Akito YamaguchiDepartment of Urology, Harasanshin Hospital, 1-8 Taihaku-machi, Hakata-ku, Fukuoka City, Fukuoka, 812-0033, Japan.
Masahiko SuzukiDepartment of Urology, Kasumigaura Medical Center, 2-7-14 Shimotakatsu, Tsuchiura City, Ibaraki, 300-0812, Japan.
Yasuyuki SakaiDepartment of Urology, National Cancer Center East, 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba, 277-8577, Japan.
Tomokazu KimuraDepartment of Urology, Faculty of Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba City, Ibaraki, 305-8575, Japan.
Manabu TakaiDepartment of Urology, Kizawa Memorial Hospital, 590 Shimokobi, Kobicho, Minokamo, Gifu, 505-8503, Japan.
Kensaku SeikeDepartment of Urology, Chuno Kosei Hospital, 5-1 Wakakusadori, Seki-city, Gifu, 501-3802, Japan.
Takahiko HashimotoDepartment of Urology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya City, Hyogo, 663-8501, Japan.
Shingo YamamotoDepartment of Urology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya City, Hyogo, 663-8501, Japan.
Gifu University · JPHarasanshin Hospital · JPHyogo Medical University · JPInternational University of Health and Welfare · JPAizawa Hospital · JPKasumigaura Medical Center · JPNational Cancer Center Hospital East · JPOkayama University · JPPublic Central Hospital of Matto Ishikawa · JPSapporo Medical University · JPUniversity of Tsukuba · JP

Funding

Japan Society for the Promotion of Science 17K11124Japan Society for the Promotion of Science 18H02934
6 · The paper itself

Abstract

backgroundTo study the outcomes and experiences of using metallic stents in treating patients with malignant ureteral obstruction (MUO), we examined the effects of metallic ureteral stenting using the Cook Resonance® stent in the treatment of MUO.

methodsAll patients who had a Resonance metallic stent inserted between April 2015 and March 2018 at one of multiple facilities were prospectively observed with a 1-year follow-up. The primary outcome was the patency rate of the metallic ureteral stent. The secondary outcomes included the complications (e.g., infection and fever).

resultsAlthough stent insertion was attempted in 50 patients, the stent could not be inserted as a ureteral stent in three patients due to severe ureteral stricture, and one ureteral cancer patient was excluded from the analysis. The remaining 46 patients' median age was 67 years (range 28-85 years) (16 males, 30 females). Twenty-four patients died during the study; their median survival time was 226 days. The median follow-up period for the censored patients was 355 days (range 16-372 days), and just seven patients were still alive without Resonance failure > 1 year later. The women's IPSS scores tended to be lower than those of the men. Regarding the OABSS score, although the women's total score tended to be low, the difference between the men's and women's scores was nonsignificant. The bacteria detected from urine culture after stent insertion were more gram-positive than gram-negative.

conclusionMetallic ureteric stenting using the Resonance stent is safe and effective for treating MUO. Subjective symptoms were relatively less in the female patients.

Indexed as

StentsAdultAgedAged, 80 and overBacterial InfectionsCreatinineFemaleFollow-Up StudiesGastrointestinal NeoplasmsGenital Neoplasms, FemaleHumansMagnetic Resonance ImagingMaleMetalsMiddle AgedProspective StudiesCreatinineMetalsMalignant ureteral obstructionMetallic ureteric stentingMetal stentResonance stentUreteral stent

Identifiers

PMID31881875
PMCPMC6935232
OpenAlexW2997639297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.